Advertisement

Immunological Biomarkers and Immunotherapy for Melanoma

  • Jochen T. SchaeferEmail author
Chapter
Part of the Current Clinical Pathology book series (CCPATH)

Abstract

Advanced melanoma is an aggressive disease. It is among the most immunogenic of all tumors and many of the lessons learned in cancer immunology have involved the study of melanoma. Clinical regression of both benign and malignant melanocytic neoplasms lends further support for the potential powerful effect of the immune system targeting these neoplasms. However, only a subset of patients shows a favorable response to immune-based therapeutic interventions. Therefore, the identification of biomarkers that may assist in identifying patients who are likely to respond to immunotherapy would be a tremendous improvement with respect to the risk/benefit ratio, patient safety and cost.

Keywords

Human Leukocyte Antigen Chimeric Antigen Receptor Immune Effector Cell Transport Associate With Antigen Processing Bacille Calmette Guerin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Harlin H, Kuna TV, Peterson AC, et al. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2009;55:1185–97.CrossRefGoogle Scholar
  2. 2.
    Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–16.PubMedGoogle Scholar
  3. 3.
    Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19:3477–82.PubMedGoogle Scholar
  4. 4.
    Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19:81–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998–1012.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909–15.PubMedCrossRefGoogle Scholar
  7. 7.
    Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst. 2002;94:805–18.PubMedGoogle Scholar
  8. 8.
    Appay VV, Jandus C, Voelter V, et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumour site. J Immunol. 2006;177:1670–8.PubMedGoogle Scholar
  9. 9.
    Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumour immunology and immunotherapy. Immunol Rev. 2006;211:214–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogenieic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol. 2007;25:2078–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Smith 2nd JW, Walker EB, Fox BA, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-­specific CD8+ T-cell responses. J Clin Oncol. 2003;21:1562–73.PubMedCrossRefGoogle Scholar
  13. 13.
    Slingluff CL, Yamshchikov G, Neese P. Phase I trial of melanoma vaccine with gp100 280–288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012–24.PubMedGoogle Scholar
  14. 14.
    Slingluff CL, Petroni G, Bullock KA, et al. Immunological results of a phase II randomized trial of multipeptide vaccines for melanoma. Proc Am Soc Clin Oncology. 2004;22(14s):abstract 7503.Google Scholar
  15. 15.
    Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. NEJM. 2011;364:2119–27.PubMedCrossRefGoogle Scholar
  16. 16.
    Brichard VG, Lejeune D. Cancer immunotherapy targeting tumor-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther. 2008;8:951–68.PubMedCrossRefGoogle Scholar
  17. 17.
    Kruit WH, Suciu S, Dreno B. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma. J Clin Oncol. 2008;26 (May 20 2008) ASCO Annual Meeting. Abstract 9065.Google Scholar
  18. 18.
    Schaefer JT, Patterson JW, Deacon DH, et al. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med. 2010;8:79.PubMedCrossRefGoogle Scholar
  19. 19.
    Tuettenberg A, Becker C, Huter E, et al. Induction of strong and persistent Melan A/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer. 2006;118:2617–27.PubMedCrossRefGoogle Scholar
  20. 20.
    Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol. 2003;170:1304–12.PubMedGoogle Scholar
  22. 22.
    Ilkovitch D, Lopez DM. Immune modulation by melanoma-derived factors. Exp Dermatol. 2008;17:977–85.PubMedCrossRefGoogle Scholar
  23. 23.
    Kim R, Emi M, Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumor and their targeted strategies for provoking tumor immunity. Clin Exp Immunol. 2006;146:189–96.PubMedCrossRefGoogle Scholar
  24. 24.
    Bergen M, Chen R, Gonzalez R. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma. Expert Opin Biol Ther. 2003;3:377–84.PubMedGoogle Scholar
  25. 25.
    Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp-96 peptide complexes: clinical and immunologic findings. J Clin Oncol. 2002;20:4169–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Pilla L, Patuzzo R, Rivoltini L, et al. A phase II trial of vaccination with autologous tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother. 2006;55:958–68.Google Scholar
  27. 27.
    Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespan, an autologout tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 study group. J Clin Oncol. 2006;26:955–62.CrossRefGoogle Scholar
  28. 28.
    Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Bendle GM, Haanen JB, Schumacher TN. Preclinical development of T cell receptor gene therapy. Curr Opin Immunol. 2009;21(2):209–14.PubMedCrossRefGoogle Scholar
  31. 31.
    Heemskerk MH, Hagedoorn RS, van der Hoorn MA, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood. 2007;109(1):235–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Fontana R, Bregni M, Cipponi A, et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. Blood. 2009;113:1651–60.PubMedCrossRefGoogle Scholar
  33. 33.
    Eggermont AM, Schadendorf D. Melanoma and immunotherapy. Hematol Oncol Clin North Am. 2009;23:547–64. Ix–x.PubMedCrossRefGoogle Scholar
  34. 34.
    Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741–50.PubMedCrossRefGoogle Scholar
  36. 36.
    O’Day S, Weber J, Lebbe C, et al. Effect of ipilimumab treatment on 18-month survival: update of patients (pts) with advanced melanoma treated with 10mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol. 2009;27(15s). abstract 9033.Google Scholar
  37. 37.
    Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics and immunologic correlates. J Clin Oncol. 2010;28:3167–75.PubMedCrossRefGoogle Scholar
  38. 38.
    Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876–83.PubMedCrossRefGoogle Scholar
  39. 39.
    Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;25:1612–6.CrossRefGoogle Scholar
  40. 40.
    Wagner SN, Pashenkov M, Goess G, et al. TLR-9-targeted CpG immunostimulatory treatment of metastatic melanoma: a phase II trial with CpG 7909 (promune). J Clin Oncol, ASCO. 2004;22(14s). abstract 7513.Google Scholar
  41. 41.
    Lehner M, Morhart P, Stilper A, et al. Efficient chemokine-dependent migration and primary and secondary IL-12 secretion by human dendritic cells stimulated through toll-like receptors. J Immunother. 2007;30:312–22.PubMedCrossRefGoogle Scholar
  42. 42.
    Birmachu W, Gleason RM, Bulbulian BJ, et al. Transcriptional networks in plamacytoid dendritic cells stimulated with TLR7 agonists. BMC Immunol. 2007;8:26.PubMedCrossRefGoogle Scholar
  43. 43.
    Stary G, Bangert C, Tauber M, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204:1441–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Parkinson DR. Levamisole as adjuvant therapy for melanoma: quo vadis? J Clin Oncol. 1991;9:716–7.PubMedGoogle Scholar
  45. 45.
    Lipton A, Harvey HA, Balch CM, et al. Corynebacterium parvum versus bacillus Calmette-Guerin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol. 1991;9:1151–6.PubMedGoogle Scholar
  46. 46.
    Hamzah J, Jungold M, Kiesssling F, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008;453(1783):410–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Kandalaft LE, Facciabene A, Buckanovich RJ, et al. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res. 2009;15:4521–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Ahmadzadeh M, Felipe-Silva A, Heemskerk B, et al. FoxP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood. 2008;112:4953–60.PubMedCrossRefGoogle Scholar
  49. 49.
    Kryczek I, Liu R, Wang G, et al. FoxP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 2009;69:3995–4000.PubMedCrossRefGoogle Scholar
  50. 50.
    Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell mediated attenuation of T-cell response to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res. 2009;15:2166–73.PubMedCrossRefGoogle Scholar
  51. 51.
    Viguier M, Lemaitre F, Verola O, et al. FoxP3 expressing CD4  +  CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173:1444–53.PubMedGoogle Scholar
  52. 52.
    Wang HY, Lee DA, Peng G, et al. Tumour-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004;20:107–18.PubMedCrossRefGoogle Scholar
  53. 53.
    Wang HY, Peng G, Guo Z, et al. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol. 2005;174:2661–70.PubMedGoogle Scholar
  54. 54.
    Mortarini R, Piris A, Maurichi A, et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-­antigens in human metastatic melanoma. Cancer Res. 2003;63:2535–45.PubMedGoogle Scholar
  55. 55.
    Zippelius A, Batard P, Rubio-Godoy V, et al. Effector function of human tumour-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004;64:2865–73.PubMedCrossRefGoogle Scholar
  56. 56.
    Baumgartner JM, Gonzalez R, Lewis KD, et al. Increased survival from stage IV melanoma associated with fewer regulatory T cells. J Surg Res. 2008;154(1):13–20.PubMedCrossRefGoogle Scholar
  57. 57.
    Kim-Schulze S, Kim HS, Fan Q, et al. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther. 2009;17:380–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Kong LY, Wei J, Sharma AK, et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2008;58(7):1023–32.PubMedCrossRefGoogle Scholar
  59. 59.
    Demotte N, Stroobant V, Courtoy PJ, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity. 2008;28:414–24.PubMedCrossRefGoogle Scholar
  60. 60.
    Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor angtigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537–44.PubMedCrossRefGoogle Scholar
  61. 61.
    Wang W, Lau R, Yu D, et al. PD1 blockade reversed the suppression of melanoma antigen-specific CTL by CD3+ CD25(Hi) regulatory T cells. Int Immunol. 2009;21:1065–77.PubMedCrossRefGoogle Scholar
  62. 62.
    Kageshita T, Ishihara T, Campoli M, Ferrone S. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens. 2005;65:419–28.PubMedCrossRefGoogle Scholar
  63. 63.
    Chang CC, Ogino T, Mullins DW, et al. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem. 2006;281:18763–73.PubMedCrossRefGoogle Scholar
  64. 64.
    Chang CC, Campoli M, Restifo NP, et al. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-­processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol. 2005;174:1462–71.PubMedGoogle Scholar
  65. 65.
    Dissemond J, Gotte P, Mors J, et al. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res. 2003;13:253–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Khan AN, Gregorie CH, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother. 2008;57:647–54.PubMedCrossRefGoogle Scholar
  67. 67.
    Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.PubMedCrossRefGoogle Scholar
  68. 68.
    Mandruzzato S, Solito S, Falisi E, et al. IL4Ralpha  + myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182:6562–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Tartour E, Blay JY, Dorval T, et al. Predictors of clinical responses to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol. 1996;14:1697–703.PubMedGoogle Scholar
  70. 70.
    Schmidt H, Suciu S, Punt CJ, et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 biochemotherapy trial. J Clin Oncol. 2007;25:1562–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Lee JE, Lu M, Mansfield PF, et al. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II. Cancer. 1996;78(4):758–63.PubMedCrossRefGoogle Scholar
  72. 72.
    Lee JE, Abdalla J, Porter GA, et al. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002;9(6):587–93.PubMedGoogle Scholar
  73. 73.
    Rubin JT, Day R, Duquesnoy R, et al. HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2. Ther Immunol. 1995;2(1):1–6.PubMedGoogle Scholar
  74. 74.
    Sabatino M, Kim-Schulze S, Panellin MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009;27:2645–52.PubMedCrossRefGoogle Scholar
  75. 75.
    Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity. Cancer J. 2010;1:399–403.CrossRefGoogle Scholar
  76. 76.
    Sullivan RJ, Hoshida Y, Brunet J, et al. A single center experience with high-dose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol 2009;27(15s). abstract 9003.Google Scholar
  77. 77.
    Butterfield LH, Isis ML, Fox BA, et al. A systematic approach to biomarker discovery; preamble to “the iSBTc-FDA taskforce on immunotherapy biomarkers”. J Transl Med. 2008;6:81.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of Connecticut Health CenterFarmingtonUSA

Personalised recommendations